Brief: Epigenomics: Cumulative Loss Of More Than Half Of Nominal Share Capital
17/04/2018 17:31
April 17 (Reuters) - Epigenomics AG ECXn.DE :
* NOTIFIES A CUMULATIVE LOSS OF MORE THAN HALF OF NOMINAL SHARE CAPITAL OF COMPANY HAS BEEN
INCURRED
* CURRENT FINANCIAL RESOURCES OF COMPANY ARE SUFFICIENT TO SUPPORT OPERATIONS BEYOND 2018
* EXECUTIVE BOARD EXPECTS TO BE ABLE TO RAISE ADDITIONAL CAPITAL IN 2018
Source text for Eikon: ID:nEQ9F7zka
Further company coverage: ECXn.DE
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Epigenomics AG
See all newsU.S. FDA advisers back approval for Guardant's blood-based cancer test (updated)
U.S. FDA advisers back approval for Guardant's cancer test
Brief: Epigenomics Says Closing Of Agreement On The Acquisition Of Almost All Assets And Adjustment Of Guidance For 2023
Brief: Epigenomics AG Says It Entered Into Agreement On The Acquisition Of Almost All Assets With New Day Diagnostics LLC
Brief: Epigenomics Says Chief Scientific Officer Andrew Lukowiak Resigns